Immunotherapy before surgery shows promise for genetic subtype of colon cancer
NCT ID NCT05116085
First seen Feb 16, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tested the drug tislelizumab given before surgery in 33 people with early-stage (stage II-III) colorectal cancer that has specific genetic changes (MSI-H or dMMR). The goal was to see if the drug could shrink or eliminate the tumor before surgical removal. The main measure was how many patients had most of their cancer cells killed by the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital of Qingdao University Branch South
Qingdao, Shandong, 266000, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233004, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.